Publications by authors named "Anya Xinyi Jiang"
Article Synopsis
- Spinal muscular atrophy (SMA) is a serious genetic disorder leading to muscle weakness, respiratory issues, and increased mortality, and this study focuses on the real-world health care costs and utilization for patients treated with disease-modifying therapies in the U.S.
- The analysis involved 74 patients under 2 years old who were treated with either nusinersen, onasemnogene abeparvovec, or both, comparing their health care resource usage and costs over more than a year after starting treatment.
- Findings showed that those treated with nusinersen had significantly higher rates of hospital visits and medical costs, while onasemnogene abeparvovec led to much higher pharmacy costs, indicating different economic impacts of these treatments
